An interventional study of MB-CART19.1 and MB-CART20.1 in Melanoma Stage III, B-cell Non Hodgkin Lymphoma and Pediatric ALL, sponsored by Miltenyi Biomedicine GmbH. Recruiting at 7 sites in Germany. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Miltenyi Biomedicine GmbH · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Melanoma with a site in Germany — 37 open to participants now, 71 under way, 20 of them phase 3. Melanoma · Germany.
Among the 284 studies in Melanoma with a site in Germany, this one is the 186th largest by planned enrollment of the 249 interventional ones that give a count, is one of 13 that started in 2024, is one of 16 with no phase, reaches primary completion later than 70 of the 70 other live ones, and was the 263rd registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →37 of the 284 studies in Melanoma with a site in Germany are open now. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Germany
Ages 18+
Bristol-Myers Squibb · Sites in Germany, United States, Belgium and 10 more countries
Ages 18+
Wuerzburg University Hospital · Sites in Germany
Ages 18+
Kupando GmbH · Sites in Germany
Ages 18+
Mitra Bio · Sites in Germany, Belgium, Spain and 1 more country
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 78 · Phase 2 124 · Phase 3 75 · Phase 4 3
First in 1995; this study’s year is marked. 13 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 162 across the 249 interventional studies, 420 across the 32 observational. Of the 182 that completed or were terminated, 90 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
202 of 284 have an industry lead sponsor. The 10 most frequent:
Miltenyi Biomedicine GmbH is the lead sponsor of 20 studies on the registry; 14 are open to participants now.
Miltenyi Biomedicine GmbH has 2 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
22 of the studies in Melanoma with a site in Germany that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT05270044Phase 3Pierre Fabre MedicamentAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. | 2027-03-31 |
| NCT04309409Phase 3University Hospital, EssenAdjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma | 2027-09 |
| NCT06112314Phase 3Immunocore LtdIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | 2027-10-16 |
Add all 22 to your calendar (.ics) → With an account.
Among the 284 studies in Melanoma with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
The focus in this trial is on the occurrence of any late adverse reactions (AR), serious adverse events (SAE), serious adverse reactions (SAR) and adverse events of special interest (AESI), i.e. relapse or progression of the underlying disease, life-threatening infections, death due to any case, new and secondary malignancies, lymphocyte counts, detection of the transgene of the CAR T cells, detection of replication-competent lentivirus (RCL), developmental tracking in pediatric patients and furthermore, assessment of the primary status of disease progression and overall survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Assessment of long-term safety and efficacy of Miltenyi CAR T treatment.
Biological: MB-CART19.1 · Biological: MB-CART20.1 · Biological: MB-CART2019.1
Assessment of long-term safety and efficacy of MB-CART19.1 treatment.
Also known as: CD19-targeting CAR T cells, Anti-CD19 CAR T cells
Assessment of long-term safety and efficacy of MB-CART20.1 treatment.
Also known as: CD20-targeting CAR T cells, Anti-CD20 CAR T cells
Assessment of long-term safety and efficacy of MB-CART2019.1 treatment.
Also known as: CD20/CD19-targeting CAR T cells, Anti-CD20/CD19 CAR T cells
Adverse Events
Percentage of patients with late-onset adverse reactions (AR), serious adverse events (SAE), serious adverse reactions (SAR) and adverse events of special interest (AESI) including relapse or progression of the underlying disease, life-threatening infections, death due to any cause, new and secondary malignancies
Time frame: through study completion, up to 14 years
Lymphocyte count
B and T lymphocyte count
Time frame: through study completion, up to 14 years
Height
Height
Time frame: through study completion, up to 14 years
Weight
Weight
Time frame: through study completion, up to 14 years
Tanner staging for pediatric patients
Tanner staging for pediatric patients
Time frame: through study completion, up to 14 years
Menstruation status for pediatric patients
Did the patient experience their first menstrual cycle (menarche)? If yes, enter date
Time frame: through study completion, up to 14 years
RCL
Percentage of patients with detectable replication-competent lentivirus (RCL) (if results of 2 consecutive years are negative for an individual patient, further sampling will not be continued for this patient; if results of all samples in first year of primary trial were negative for an individual patient, sampling will not be continued for this patient in this long-term follow-up trial)
Time frame: through study completion, up to 14 years
Relapse / Progression
Percentage of patients who relapse or progress since enrollment and rate of surviving patients
Time frame: through study completion, up to 14 years
Detectable Transgene levels
Percentage of patients with detectable transgene levels (if results of 2 consecutive years are negative for an individual patient, further sampling will be stopped for this patient)
Time frame: through study completion, up to 14 years
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Dec 2040, 199 months after the start.
Of 227 interventional studies with no phase under Melanoma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 199 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1 · Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1 · Zamtocabtagene autoleucel
Miltenyi Biomedicine GmbH